1. Home
  2. CLLS

CLLS

Cellectis S.A.

Logo Cellectis S.A.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 1:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Founded: 1999 Country:
France
France
Employees: N/A City: N/A
Market Cap: 193.6M IPO Year: 2007
Target Price: $8.50 AVG Volume (30 days): 37.8K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.76 EPS Growth: N/A
52 Week Low/High: $0.96 - $3.77 Next Earning Date: 05-02-2024
Revenue: $24,410,000 Revenue Growth: N/A
Revenue Growth (this year): -35.42% Revenue Growth (next year): 35.03%

Share on Social Networks: